The Next Generation of Personalized Medicine: A Comprehensive Review
DOI:
https://doi.org/10.32628/IJSRST2512240Keywords:
Personalized medicine, Challenges, Genomes, targeted therapy, proteoforms, proteoformicsAbstract
The pharmaceutical sector is nevertheless confronted with formidable obstacles. These days Drug research and the advancement of healthcare systems are two areas in which personalized medicine is significantly contributing. Personalized medicine, also known as precision medicine. The basic principle of personalized medicine is that the appropriate drug should be administered to the appropriate patient at the appropriate time for the appropriate period of time. The approach depends on gathering clinical, genetic, and epigenomic data that improves our comprehension of how an individual's distinct genomic inventory contributes to particular diseases. The current standard in the field of specific medication therapy is protein medicines. They are more effective in regulating the biological processes connected to disease because they have better biological activity and target specificity than small molecule pharmacological medications. They also hold great promise for the creation of personalized drugs. As proteoformics research progresses, personalized medication therapy—particularly specific protein medications that target proteoforms as a drug target will advance knowledge of disease mechanisms, identify new drug targets and signalling routes, offer a theoretical foundation for the creation of new medications, assist physicians in performing evaluations of health risks and developing more affordable targeted prevention strategies using AI and machine learning, foster innovation in technology, and offer more convenient treatment based on a The distinct profile of the patient, all of which will be advantageous to both the affected people and the community at large. This strategy is a full continuation of the advanced method for improving our capacity to forecast which medical interventions will be secure and successful for each patient.
Downloads
References
Edward A, Ginsburg GS, Silver M, The personalized Medicine Coalition: goals and strategies, American journal of Pharmacogenomics,2005;5(6): 345-355.DOINO:10.2165/00129785-200505060-00002; PMID:16336000.
Sadée W and Dai Z: Pharmacogenetics/genomics and person¬alized medicine. Hum Mol Genet 14: R207 R214, 2005.
Sanzo MD, Cipollini L, Borro M, Russa RL, Clinical Application of Personalized Medicine: A new paradigm and challenge, Current Pharmaceutical Biotechnology,2017;18(3):194-203.
Kulkarni A and Padilla N: A Strategist's Guide to Personalized Medicine. Strategy and Business 75: Summer 2014, 2014.
Vogenberg FR, Barash C Isaacson and Pursel M: Personalized medicine: Part 1: Evolution and development into theranostics. P T., 2010, 35, 560–576.
Vogenberg FR.; Barash CI and Pursel M: Personalized medicine: Part 2: Ethical, legal, and regulatory issues. P T., 2010, 35, 624–642.
Hamburg MA and Collins FS., N Engl J Med., 2010, 363, 301–304.
Sairamesh J and Rossbach M: An economic perspective on personalized medicine. HUGO J 7: 1, 2013.
Association of the British Pharmaceutical Industry: The stratification of disease for personalised medicines. http://www.abpi.org.uk/ our work/library/medical disease/Pages/person¬alised medicines.aspx. Accessed April 16, 2009.
FDA Focus area: individualized therapeutics and precision medicine. September 6, 2022.
FDA takes steps to provide clarity on developing new drug products in the age of individualized medicine. January 4, 2021.
FDA IND submissions for individualized antisense oligonucleotide drug products administrative and procedural recommendations guidance for sponsor-investigators. January 2021.
Jelliffe, R. (2000) Goal-oriented, model-based drug regimens: setting individualized goals for each patient. Ther. Drug Monit. 22, 325–329
Daly, A. K. (2007) Individualized drug therapy. Curr. Opin. Drug Discov. Dev. 10, 29–36
Spigset, O. (2000) Fra konfeksjon til skreddersøm–fremtidige muligheter for individuelt tilpasset legemiddelbehandling from ready-made to tailormade– future possibilities for individualized drug therapy. Tidsskr. Nor. Laegeforen. 120, 73–76
Aarbakke, J. (2000) Who will receive future tailor-made drugs? Tidsskr. Nor. Laegeforen. 120, 77
Steen, V. M. (2000) Skreddersøm av legemidler i et nytt millennium tailormade drugs in the new millennium. Tidsskr. Nor. Laegeforen. 120, 76–77
Nohmi, T. (2002) Drug discovery based on genomic information. Rinsho Byori 50, 694–697.
Ferriols Lisart, F., and Ferriols Lisart, R. (2003) Pharmacogenetics: where are we and where are we going to? Farm. Hosp. 27, 109–120
Chivda VP, Tailor-made Medicine: A step towards future of Diagnostic and Therapeutic, PharmaTutor,2015;3(11):25- 18.
Phillips, K. A.; Veenstra, D. L., & Oren, E., Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review., JAMA., 2008, 299(23), 2736–2744
Pirmohamed, M., & Hughes, D. A., The pharmacogenomics Journal., 2018, 18(2),203–207.
Schilsky, R. L., Personalized medicine in oncology: the future is now., Nature Reviews Drug Discovery., 2010, 9(5), 363-366.
Le Tourneau, C.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.,... & Massard, C., The Lancet Oncology., 2015, 16(13), 1324–1334.
Feiler T, Gaitskell K, Maughan T, etal., Personalized Medicine: The promise, the Hype and the Pitfalls, The New Bioethics, A Multidisciplinary Journal of Biotechnology and theBody,2017;23(1):1-12. DOI:10.1080/20502877.2017.1314895; PMID:28517985.
Harvey A, Brand A, Holgate ST, etal., The future of technologies for personalized medicine, NewBiotechnology, 2012;29(6): 625633.DOINO: 10.1016/j.nbt.2012.03.009; PMID NO:23091837.
Smith, S. A., and Smith, S. E. (1980) Subsensitivity to cholinoceptor stimulation of the human iris sphincter in situ following acute and chronic administration of cholinomimetic miotic drugs. Br. J. Pharmacol. 69, 513–518.
Alm, A., and Nilsson, S. F. (2009) Uveoscleral outflow–a review. Exp. Eye Res. 88, 760–768.
Khoury, M. J., Iademarco, M. F., & Riley, W.American Journal of Preventive Medicine,2016, 50(3), 398-401.
Mirnezami, R., Nicholson, J., & Darzi, A., New England Journal of Medicine., 2021, 366(6), 489-491.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 International Journal of Scientific Research in Science and Technology

This work is licensed under a Creative Commons Attribution 4.0 International License.